ClinicalTrials.gg
Not yet recruitingNCT07659080NOMAUpdated Aug 10, 2026

Antireflux Surgery Without Preoperative Esophageal Manometry

An interventional study of Preoperative workup without high-resolution esophageal manometry and Standard preoperative workup with high-resolution esophageal manometry in GERD, Hiatal Hernia and Heartburn, sponsored by McMaster University. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by McMaster University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if people can safely skip a test called esophageal manometry before surgery for acid reflux (gastroesophageal reflux disease, or GERD) or a hiatal hernia. Manometry measures the muscles of the food pipe using a thin tube passed through the nose. The test can be uncomfortable and can delay surgery. The main questions this study aims to answer are whether people can skip manometry and still have good swallowing one year after surgery, and whether skipping the test lowers discomfort, shortens the wait for surgery, and lowers cost. To answer this, researchers will compare two groups. One group will have surgery without manometry. The other group will have manometry first, the way it is usually done. Everyone will get the same operation, a partial wrap called a Toupet fundoplication, so the study tests the value of the test and not the surgery. Participants will be placed by chance into one of the two groups, have the same standard operation, and fill out short questionnaires about their swallowing before surgery and again at 3, 6, and 12 months after surgery. Researchers want to find out if skipping manometry works just as well as the usual approach for people who do not have trouble swallowing before surgery.

Read the detailed description

BACKGROUND AND RATIONALE Gastroesophageal reflux disease (GERD) and hiatal hernia are among the most common indications for foregut surgery. Laparoscopic antireflux surgery is a durable option for patients who fail or cannot tolerate proton pump inhibitor therapy. The Toupet 270-degree posterior partial fundoplication has become the preferred wrap at high-volume centers because it provides reflux control comparable to the complete Nissen wrap while producing significantly less postoperative dysphagia, as demonstrated across randomized trials and network meta-analysis.

High-resolution esophageal manometry (HRM) has traditionally been performed as part of the routine preoperative workup before antireflux surgery. Its historical rationale was threefold: to exclude major motility disorders such as achalasia, to characterize lower esophageal sphincter function, and to detect ineffective esophageal motility in order to guide wrap selection toward a partial fundoplication. The 2023 multi-society consensus guideline on the treatment of GERD now recommends a partial fundoplication for patients with either normal or abnormal manometry findings, which establishes the partial wrap as standard of care regardless of the manometry result. When the operation is already standardized to a Toupet wrap, the principal justification for routine manometry, namely wrap selection, is removed.

Manometry is not without burden. It requires transnasal catheter placement and esophageal intubation, is frequently reported as uncomfortable, adds scheduling delays of several weeks in publicly funded systems, and carries a direct cost of approximately 500 to 1,500 US dollars per patient. In patients without overt dysphagia, the prevalence of clinically unsuspected major motility disorders is consistently estimated at less than 2 to 5 percent. Despite this, whether manometry can be safely omitted in this carefully selected population has never been evaluated in a prospective randomized trial. This trial addresses that evidence gap.

OBJECTIVES AND HYPOTHESIS The primary objective is to determine whether upfront laparoscopic Toupet 270-degree fundoplication without preoperative manometry is non-inferior to standard manometry-guided care with respect to patient-reported dysphagia at 12 months. The investigators hypothesize that omitting manometry is non-inferior to standard care, because the operation is identical in both arms and patients most likely to harbor an unsuspected motility disorder are excluded at screening. Secondary objectives are to compare reflux-related quality of life, proton pump inhibitor use, 30- and 90-day complications, patient-reported procedural discomfort and anxiety, time from referral to surgery, and direct cost, and to quantify how often manometry findings would have altered operative management.

STUDY DESIGN AND SETTING This is a prospective, multicenter, open-label, randomized controlled non-inferiority trial conducted at St. Joseph's Healthcare Hamilton (McMaster University) and Cleveland Clinic. Both sites are high-volume foregut centers with dedicated esophageal motility laboratories, which supports recruitment and the safe management of any participant who requires manometry during the trial.

RANDOMIZATION AND ALLOCATION CONCEALMENT Participants are randomized 1:1 through a central, web-based system with concealed allocation, using variable permuted blocks. Randomization is stratified by site, hernia type, and pH testing status. Because ambulatory pH testing is performed at the discretion of the treating surgeon and may influence outcomes independently, pH testing status is used as a stratification variable so that participants who undergo pH testing are balanced between arms, and those who do not are likewise balanced. This preserves internal validity and supports a prespecified subgroup analysis.

BLINDING Patients and surgeons cannot be blinded to allocation given the nature of the intervention. Outcome assessors and data analysts are blinded to allocation.

STUDY ARMS AND INTERVENTION Participants in the no-manometry arm undergo endoscopy and imaging (computed tomography or upper gastrointestinal study) without preoperative manometry, and proceed directly to surgery. Participants in the standard-workup arm undergo the same endoscopy and imaging plus high-resolution esophageal manometry within eight weeks before surgery. Ambulatory pH testing may be performed at the surgeon's discretion in either arm per institutional practice.

In both arms the operation is identical. All participants undergo a standardized laparoscopic Toupet 270-degree posterior partial fundoplication with hiatal hernia repair. The operative standard is defined by a technique manual and includes a five-port laparoscopic approach, complete circumferential gastroesophageal junction dissection, posterior cruroplasty with interrupted non-absorbable sutures, at least 2.5 centimeters of tension-free intra-abdominal esophageal length, and wrap construction sutured to the esophageal wall bilaterally. Intraoperative endoscopy is mandatory in all cases to confirm wrap calibration and adequacy. The operative approach does not vary with manometry findings; this standardization is the key design feature that removes the conventional justification for routine manometry.

CROSSOVER AND SAFETY Crossover from the no-manometry arm to manometry is permitted only for intraoperative findings highly suggestive of a primary motility disorder, such as failure of lower esophageal sphincter relaxation or a bird-beak appearance. In such cases the operation is aborted and manometry is arranged postoperatively. Both participating sites have dedicated motility laboratories capable of high-resolution manometry and ambulatory pH testing to manage any such participant. All crossovers are analyzed in the intention-to-treat population and documented as protocol deviations for the per-protocol analysis. This is a minimal-risk trial in which both arms receive standard-of-care surgery; safety is monitored by the investigators through systematic capture of surgical complications graded by the Clavien-Dindo classification.

SCHEDULE OF ASSESSMENTS Assessments are collected at screening, baseline, the preoperative visit, surgery, and at 3, 6, and 12 months after surgery. Patient-reported outcomes are administered at baseline and at each postoperative timepoint and are captured electronically in a secure, access-controlled REDCap database hosted through McMaster University, with paper backup. Surgical complications are recorded at 30 and 90 days.

SAMPLE SIZE The sample size is based on the primary outcome. Assuming an expected mean dysphagia score of 0.35 with a standard deviation of 0.80, a non-inferiority margin of 0.5 points, a two-sided alpha of 0.05, and 80 percent power, approximately 40 participants per arm are required. Allowing for a conservative 15 percent dropout, the enrollment target is 48 participants per arm, for a total of 96 participants.

STATISTICAL ANALYSIS Non-inferiority will be concluded if the upper bound of the two-sided 95 percent confidence interval for the between-arm difference in the primary outcome lies below the prespecified margin of 0.5 points, using a two-sample t-test or a Wilcoxon rank-sum test if the normality assumption is not met. The primary analysis is by intention to treat, with a per-protocol analysis performed as a sensitivity analysis. Secondary outcomes will be analyzed using mixed-effects models for repeated measures, Kaplan-Meier estimation with log-rank testing for time-to-event outcomes, and Fisher exact tests for proportions. Missing data will be handled using multiple imputation under a missing-at-random assumption. A prespecified subgroup analysis by pH testing status will be performed for the primary outcome.

DATA MANAGEMENT AND MONITORING Study data are recorded under a unique study identifier, with the linking key stored separately and securely and accessible only to the local study team. The trial is minimal risk and does not use a formal data safety monitoring board; the investigators review enrollment, protocol deviations, and adverse events during accrual, and report serious adverse events and unanticipated problems to the research ethics board within required timelines.

ETHICS AND REGISTRATION The trial holds ethics approval from the Hamilton Integrated Research Ethics Board and will be conducted in accordance with the Tri-Council Policy Statement, Good Clinical Practice, and applicable institutional and regulatory requirements at each site. The trial is registered on ClinicalTrials.gov before enrollment of the first participant.

SIGNIFICANCE This trial provides the first randomized evidence on whether preoperative manometry can be safely omitted before standardized partial fundoplication in patients without overt dysphagia. A finding of non-inferiority would support simplifying the preoperative pathway, shortening time to surgery, improving patient experience, and reducing cost, and could inform practice guidelines internationally. A neutral result would clarify the true clinical utility of manometry and support more selective rather than routine testing.

02

Conditions studied

  • GERD
  • Hiatal Hernia
  • Heartburn
  • Paraesophageal Hernia
  • Gastroesophageal Reflux

Keywords

  • GERD
  • hiatal hernia
  • fundoplication
  • Gastroesophageal Reflux Disease
  • Paraesophageal Hernia
03

In context

Gastroesophageal Reflux

1,211 studies on the registry are indexed under Gastroesophageal Reflux; 202 are open to participants now.

This study's planned enrollment of 96 is above the median of 68 across 796 interventional studies indexed under Gastroesophageal Reflux.

Browse Gastroesophageal Reflux studies →

Lead sponsor

McMaster University is the lead sponsor of 741 studies on the registry; 127 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Documented GERD and/or hiatal hernia (Type I, II, or small Type III) confirmed on EGD and/or imaging (i.e. CT scan or upper GI study) within 12 months
  3. Presence of at least one guideline-based indication for antireflux surgery:

    1. Typical GERD symptoms (heartburn and/or regurgitation) to or recurrent after adequate PPI therapy
    2. PPI-dependent GERD with patient preference for surgical management
    3. Extra-esophageal GERD symptoms (chronic cough, laryngitis, asthma) with pathologic reflux confirmed on ambulatory pH study
    4. Symptomatic Type II/III paraesophageal hernia (postprandial pain, early satiety, dysphagia to solids)
    5. Objective documentation of pathologic esophageal acid exposure on ambulatory reflux monitoring (24-hour pH-impedance or 48-hour Bravo pH capsule) confirming GERD diagnosis, performed within 12 months of enrollment
  4. Mellow-Pinkas dysphagia score = 0 at baseline (no overt dysphagia)
  5. Eckardt score \< 1 (achalasia screening)
  6. Ability to provide and comply with 12-month follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Overt dysphagia (Mellow-Pinkas ≥ 1 or Eckardt ≥ 1)
  2. Prior esophageal or gastric surgery
  3. Known or clinically suspected achalasia or primary motility disorder
  4. Endoscopic stricture, mass, or luminal obstruction
  5. Giant paraesophageal hernia (Type IV, or Type III with >50% of stomach herniated intrathoracically)
  6. Connective tissue disease with esophageal involvement (e.g., scleroderma/CREST)
  7. Active esophageal or gastric
  8. Pregnancy
  9. > 40 kg/m² (patients with severe obesity who would be candidates for bariatric surgery should be referred for metabolic/bariatric evaluation, as per the multi-society GERD guideline recommending weight-loss surgery consideration in this population)
  10. Participation in another interventional trial within 30 days
  11. Prior esophageal manometry within 12 months demonstrating a major motility disorder (achalasia, absent contractility, distal esophageal spasm, hypercontractile esophagus); such patients should be managed per standard motility disorder pathways and are not candidates for this trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    No Manometry Arm

    Participants undergo EGD and imaging, with optional ambulatory pH testing at the discretion of the treating surgeon. High-resolution esophageal manometry is omitted before surgery. Participants proceed to standardized laparoscopic Toupet 270-degree posterior partial fundoplication with hiatal hernia repair.

    Procedure: Preoperative workup without high-resolution esophageal manometry

  • Active comparator
    Standard Manometry Arm

    Participants undergo a standard preoperative workup, including EGD, imaging, optional ambulatory pH testing at the discretion of the treating surgeon, and high-resolution esophageal manometry before surgery. Participants proceed to standardized laparoscopic Toupet 270-degree posterior partial fundoplication with hiatal hernia repair.

    Procedure: Standard preoperative workup with high-resolution esophageal manometry

Interventions

  • ProcedurePreoperative workup without high-resolution esophageal manometry

    Participants assigned to this intervention will not undergo routine high-resolution esophageal manometry before surgery. They will complete the remaining preoperative assessment, including EGD and imaging, with ambulatory pH testing performed only if clinically indicated at the discretion of the treating surgeon.

  • ProcedureStandard preoperative workup with high-resolution esophageal manometry

    Participants assigned to this intervention will undergo a standard preoperative workup, including EGD, imaging, optional ambulatory pH testing at the treating surgeon's discretion, and high-resolution esophageal manometry before surgery. Participants will then proceed to standardized laparoscopic Toupet 270-degree posterior partial fundoplication with hiatal hernia repair.

06

What researchers measure

Primary outcomes

  1. Mellow-Pinkas dysphagia score at 12 months

    Patient-reported dysphagia will be measured using the Mellow-Pinkas dysphagia scale. Scores range from 0 to 4, where 0 indicates no dysphagia and 4 indicates inability to swallow, including saliva. Higher scores indicate worse dysphagia.

    Time frame: 12 months postoperatively

Secondary outcomes

  1. Gastroesophageal Reflux Disease Health-Related Quality of Life score

    Reflux-related quality of life will be measured using the Gastroesophageal Reflux Disease Health-Related Quality of Life questionnaire. Total scores range from 0 to 45, with higher scores indicating worse reflux-related symptoms and quality of life.

    Time frame: 3, 6, and 12 months postoperatively

  2. Proton pump inhibitor use

    Use of proton pump inhibitor medication will be recorded, including whether the participant is using PPI therapy after surgery.

    Time frame: 3, 6, and 12 months postoperatively

  3. Postoperative complications

    Postoperative complications will be recorded and graded using the Clavien-Dindo classification.

    Time frame: 30 and 90 days postoperatively

  4. Repeat non-routine endoscopy

    The incidence of repeat non-routine endoscopy after surgery will be recorded.

    Time frame: 3, 6, and 12 months postoperatively

  5. Postoperative manometry ordered

    The incidence of postoperative manometry ordered after surgery will be recorded.

    Time frame: 3, 6, and 12 months postoperatively

  6. Procedural discomfort numeric rating scale score

    Patient-reported discomfort related to preoperative testing will be measured using an 11-point numeric rating scale. Scores range from 0 to 10, where 0 indicates no discomfort and 10 indicates the worst discomfort imaginable. Higher scores indicate greater discomfort (manometry arm only).

    Time frame: Baseline and preoperative visit

  7. Short-form State-Trait Anxiety Inventory 6-item anxiety score

    Anxiety related to preoperative testing will be measured using the Short-form State-Trait Anxiety Inventory 6-item questionnaire. Raw scores range from 6 to 24 and may be scaled to 20 to 80, with higher scores indicating greater anxiety.

    Time frame: Baseline and preoperative visit

  8. Referral-to-surgery interval

    The number of days from surgical consultation or referral to the date of surgery will be recorded.

    Time frame: At surgery, up to 18 months after enrollment

  9. Direct cost associated with manometry omission

    Institution-level direct costs associated with high-resolution esophageal manometry will be compared between study arms.

    Time frame: Through study completion, an average of 18 months

  10. DeMeester score at 12 months

    DeMeester score will be recorded among participants with available ambulatory pH testing. Scores have a minimum value of 0 and no fixed maximum; higher scores indicate greater esophageal acid exposure.

    Time frame: 12 months postoperatively

07

Study locations

2 sites
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    • Salvador Navarrete, MD · Contactnavarrs@ccf.org · 216-444-2200
    • Salvador Navarrete, MD · Principal investigator
  • St Joseph's Healthcare, McMaster University
    Hamilton, Ontario L8N 4A6, Canada
    • Yung Lee, MD MPH · Contactyung.lee@medportal.ca · 4167327306
    • Yung Lee, MD MPH · Principal investigator
    • Dennis Hong, MD MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not planned to be shared publicly at this time because the study involves patient-level clinical data and will be subject to institutional privacy, ethics, and data governance requirements. Any future data-sharing requests would require review and approval by the study investigators and applicable institutional review bodies.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07659080
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Yung LEE
Contact
yung.lee@medportal.ca
416-732-7306

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion